Treatment of human prostate cancer cell lines DU145 and 22Rv1, known for high constitutive EZH2 expression, with luteolin significantly reduced EZH2 and suppressor of zeste 12 (SUZ12) protein levels in a dose- and time-dependent manner. This evidence concerns the gene SUZ12 and prostate carcinoma.